Rick Winningham - Theravance Biopharma Chairman
| TBPH Stock | USD 9.12 0.02 0.22% |
Chairman
Mr. Rick E. Winningham serves as the Chairman of the Board, Chief Executive Officer of the Company. He has served as our Chief Executive Officer since our spinoff from Innoviva in June 2014. From October 2001 to August 2014, Mr. Winningham served as Chief Executive Officer of Innoviva, where he also served as Chairman of the board of directors from April 2010 to October 2014. From 1997 to 2001 he served as President, Bristol Myers Squibb OncologyImmunologyOncology Therapeutics Network and also as President of Global Marketing from 2000 to 2001. In addition to operating responsibility for U.S. OncologyImmunologyOTN at Bristol Myers Squibb, Mr. Winningham also had full responsibility for Global Marketing in the Cardiovascular, Infectious Disease, Immunology, OncologyMetabolics and GUGINeuroscience therapeutic areas. Over a fifteen year period beginning in 1986 with BMS and its predecessor, Bristol Myers, Mr. Winningham held various U.S. and global management positions. Mr. Winningham is a member of Biotechnology Industry Organization board of directors and serves on the Health Section Governing Board Standing Committee on Reimbursement. Mr. Winningham served as a Director on the board of directors of the California Healthcare Institute from November 2011 to March 2015. He was elected Chairman of CHI in January 2014, a position he held until CHI merged with Baybio to become the California Life Sciences Association in March 2015. Mr. Winningham is on the board of CLSA, and served as its chairman from March 2015 to November 2015. He is a member of the board of directors of Jazz Pharmaceuticals plc and of OncoMed Pharmaceuticals, Inc
| Age | 58 |
| Professional Marks | MBA |
| Address | 901 Gateway Boulevard, South San Francisco, CA, United States, 94080 |
| Phone | 650 808 6000 |
| Web | https://www.theravance.com |
Rick Winningham Latest Insider Activity
Tracking and analyzing the buying and selling activities of Rick Winningham against Theravance Biopharma stock is an integral part of due diligence when investing in Theravance Biopharma. Rick Winningham insider activity provides valuable insight into whether Theravance Biopharma is net buyers or sellers over its current business cycle. Note, Theravance Biopharma insiders must abide by specific rules, including filing SEC forms every time they buy or sell Theravance Biopharma'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Rick Winningham over a month ago Acquisition by Rick Winningham of 00 shares of Theravance Biopharma subject to Rule 16b-3 | ||
Rick Winningham over three months ago Payment of 15804 shares by Rick Winningham of Theravance Biopharma subject to Rule 16b-3 | ||
Rick Winningham over six months ago Payment of 15804 shares by Rick Winningham of Theravance Biopharma subject to Rule 16b-3 | ||
Rick Winningham over six months ago Acquisition by Rick Winningham of 3075 shares of Jazz Pharmaceuticals subject to Rule 16b-3 |
Theravance Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.0673) % which means that it has lost $0.0673 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1686) %, meaning that it created substantial loss on money invested by shareholders. Theravance Biopharma's management efficiency ratios could be used to measure how well Theravance Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.15. The Theravance Biopharma's current Return On Capital Employed is estimated to increase to -0.14. As of now, Theravance Biopharma's Non Current Assets Total are increasing as compared to previous years. The Theravance Biopharma's current Non Currrent Assets Other is estimated to increase to about 212.4 M, while Other Current Assets are projected to decrease to under 8.4 M.Similar Executives
| Found 8 records | CHAIRMAN Age | ||
| Gary Crocker | Merrimack Pharmaceuticals | 66 | |
| William Ringo | Assembly Biosciences | 71 | |
| Sean DPHIL | CytomX Therapeutics | 57 | |
| Alan Danson | Instil Bio | N/A | |
| Bruce Harker | Instil Bio | N/A | |
| Sumit Mazumder | Instil Bio | 69 | |
| Jeremy Levin | Ovid Therapeutics | 64 | |
| Hoyoung Huh | CytomX Therapeutics | 47 | |
Management Performance
| Return On Equity | -0.17 | ||||
| Return On Asset | -0.0673 |
Theravance Biopharma Leadership Team
Elected by the shareholders, the Theravance Biopharma's board of directors comprises two types of representatives: Theravance Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Theravance. The board's role is to monitor Theravance Biopharma's management team and ensure that shareholders' interests are well served. Theravance Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Theravance Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Young, Director | ||
| Andrew MBA, VP CFO | ||
| Rick Winningham, Chairman, CEO and Member of Science and Technology Committee | ||
| Stuart Knight, VP Officer | ||
| Gail Cohen, Vice Relations | ||
| Richard Graham, Strategic Advisor | ||
| Renee Gala, CFO, Sr. VP and Treasurer | ||
| Donal OConnor, Independent Director | ||
| Bradford Shafer, Sr. VP, General Counsel and Secretary | ||
| Sharathchandra Hegde, Senior Vice President Research | ||
| Junning Lee, Sr. VP of Technical Operations | ||
| George Whitesides, Director | ||
| Laurie Alsup, Independent Director | ||
| Brett Haumann, VP Clinical Devel. and Operations | ||
| Philip Worboys, Senior Vice President Translational Science | ||
| Robert Gunderson, Director | ||
| Rick MBA, Chairman CEO | ||
| Henrietta Fore, Director | ||
| Brett Esq, General VP | ||
| Dean Mitchell, Director | ||
| Mathai Mammen, Senior Vice President - Research and Development | ||
| Eran Broshy, Director | ||
| Andrew Hindman, CFO, Senior Vice President | ||
| Ann Brady, President - Theravance Biopharma Ireland Limited | ||
| Kenneth Pitzer, Senior Vice President Product Strategy and Commercial Planning | ||
| Burton Malkiel, Director | ||
| Susan Molineaux, Independent Director | ||
| Aziz CFA, Senior CFO | ||
| Leonard Blum, Senior Vice President Chief Commercial Officer | ||
| Rhonda Farnum, Chief Affairs | ||
| Peter Ringrose, Director | ||
| Shehnaaz Suliman, Senior Vice President - Corporate Development and Strategy | ||
| Stacy Pryce, Senior Officer | ||
| Sharath Hegde, Senior Vice President Research | ||
| Vijay Sabesan, Senior Vice President - Technical Operations | ||
| Aine Miller, VP Dev | ||
| Frank Pasqualone, Sr. VP of Operations |
Theravance Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Theravance Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.17 | ||||
| Return On Asset | -0.0673 | ||||
| Profit Margin | (0.96) % | ||||
| Operating Margin | (0.36) % | ||||
| Current Valuation | 386 M | ||||
| Shares Outstanding | 48.56 M | ||||
| Shares Owned By Insiders | 14.51 % | ||||
| Shares Owned By Institutions | 85.49 % | ||||
| Number Of Shares Shorted | 6.43 M | ||||
| Price To Earning | (6.20) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Theravance Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Theravance Biopharma's short interest history, or implied volatility extrapolated from Theravance Biopharma options trading.
Currently Active Assets on Macroaxis
When determining whether Theravance Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Theravance Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Theravance Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Theravance Biopharma Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theravance Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Complementary Tools for Theravance Stock analysis
When running Theravance Biopharma's price analysis, check to measure Theravance Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theravance Biopharma is operating at the current time. Most of Theravance Biopharma's value examination focuses on studying past and present price action to predict the probability of Theravance Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theravance Biopharma's price. Additionally, you may evaluate how the addition of Theravance Biopharma to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |
Is Theravance Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Theravance Biopharma. If investors know Theravance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Theravance Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.00) | Revenue Per Share 1.038 | Quarterly Revenue Growth 0.199 | Return On Assets (0.07) | Return On Equity (0.17) |
The market value of Theravance Biopharma is measured differently than its book value, which is the value of Theravance that is recorded on the company's balance sheet. Investors also form their own opinion of Theravance Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Theravance Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Theravance Biopharma's market value can be influenced by many factors that don't directly affect Theravance Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Theravance Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Theravance Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Theravance Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.